Effective October 1, 2023, the Alliance will be implementing changes to the physician-administered drug benefit. The changes are as follows:
| HCPCS Code | Drug | Change |
| J7318 | Hyaluronan or derivative, Durolane | No Change; Requires a prior authorization |
| J7320 | Hyaluronan or derivate, Genvisc 850 | Require a prior authorization |
| J7321 | Hyaluronan or derivative, Hyalgan, Supartz or Visco-3 | No Change; Requires a prior authorization |
| J7322 | Hyaluronan or derivative, Hymovis | No Change; Requires a prior authorization |
| J7323 | Hyaluronan or derivative, Euflexxa | No Change; Requires a prior authorization |
| J7324 | Hyaluronan or derivative, Orthovisc | No Change; Requires a prior authorization |
| J7325 | Hyaluronan or derivative, Synvisc or Synvisc-One | No Change; Requires a prior authorization |
| J7326 | Hyaluronan or derivative, Gel-One | No Change; Requires a prior authorization |
| J7327 | Hyaluronan or derivate, Monovisc | Require a prior authorization |
| J7328 | Hyaluronan or derivative, Gelsyn-3 | No Change; Requires a prior authorization |
| J7329 | Hyaluronan or derivate, Trivisc | No Change; Non benefit |
| J7331 | Hyaluronan or derivative, Synojoynt | No Change; Requires a prior authorization |
| J7332 | Hyaluronan or derivative, Triluron | No Change; Requires a prior authorization |
